Skip to main
BBNX

BBNX Stock Forecast & Price Target

BBNX Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 56%
Buy 22%
Hold 22%
Sell 0%
Strong Sell 0%

Bulls say

Beta Bionics Inc. has demonstrated strong financial momentum, reporting a 57% year-over-year increase in net patient starts (NPS) alongside a higher-than-expected pharmacy channel mix, which has positively influenced their revenue outlook. The company has raised its revenue estimates for 2025 and 2026, projecting figures of $97.5 million and $136 million, respectively, signaling a robust growth trajectory supported by successful market expansion efforts. With the addition of 20 new sales territories and continued strong performance in the insulin pump market, Beta Bionics is positioned for sustained premium growth, anticipating a compound annual growth rate (CAGR) of 30-40% from 2024 to 2028.

Bears say

The negative outlook on Beta Bionics Inc.'s stock primarily arises from several fundamental risks affecting revenue and profitability, including challenges with market share acquisition for its iLet product amidst competitive pressures and a potential inability to penetrate the pharmacy channel effectively. Additionally, delays in clinical development timelines and uncertainty surrounding FDA approvals may hinder the adoption of their products, particularly in Type 2 diabetes management, complicating market penetration further. The company may face financial strain requiring additional capital, which could dilute shareholder equity, compounded by unfavorable Medicare reimbursement changes and a broader slowdown within the small-cap MedTech sector impacting valuation and performance.

BBNX has been analyzed by 9 analysts, with a consensus rating of Buy. 56% of analysts recommend a Strong Buy, 22% recommend Buy, 22% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Beta Bionics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Beta Bionics Inc (BBNX) Forecast

Analysts have given BBNX a Buy based on their latest research and market trends.

According to 9 analysts, BBNX has a Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $24, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $24, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Beta Bionics Inc (BBNX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.